Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer

BMC Urology

Comment

Sophie Plagakis¹  Armando Stabile²  Alberto Briganti²  Riccardo Leni²  Giorgio Gandaglia²  Francesco Montorsi² 

[1] Flinders Medical Center, Adelaide, Australia;Unit of Urology/Division of Oncology; URI, IRCCS Ospedale San Raffaele, Milan, Italy;Vita-Salute San Raffaele University, Milan, Italy;

关键词: Prostate cancer;    Active surveillance;    Intermediate risk;    Radical prostatectomy;    Recurrence;   

DOI  :  10.1186/s12894-023-01315-5

 received in 2023-07-19, accepted in 2023-09-03,  发布年份 2023

来源: Springer

【 摘 要 】

Active surveillance has been proposed as a therapeutic option in selected intermediate risk patients with biopsy grade group 2 prostate cancer. However, its oncologic safety in this setting is debated. Therefore, we conducted a non-systematic literature research of contemporary surveillance protocols including patients with grade group 2 disease to collect the most recent evidence in this setting. Although no randomized controlled trial compared curative-intent treatments, namely radical prostatectomy and radiotherapy vs. active surveillance in patients with grade group 2 disease, surgery is associated with a benefit in terms of disease control and survival when compared to expectant management in the intermediate risk setting. Patients with grade group 2 on active surveillance were at higher risk of disease progression and treatment compared to their grade group 1 counterparts. Up to 50% of those patients were eventually treated at 5 years, and the metastases-free survival rate was as low as 85% at 15-years. When considering low- and intermediate risk patients treated with radical prostatectomy, grade group 2 was one of the strongest predictors of grade upgrading and adverse features. Available data is insufficient to support the oncologic safety of active surveillance in all men with grade group 2 prostate cancer. Therefore, those patients should be counselled regarding the oncologic efficacy of upfront active treatment modalities and the lack of robust long-term data supporting the safety of active surveillance in this setting.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023